Chicago Medicine 25th University of Chicago Comprehensive Cancer Center Developmental Therapeutics Symposium 2022

Chicago Medicine 25th University of Chicago Comprehensive Cancer Center Developmental Therapeutics Symposium 2022

Regular price
$20.00
Sale price
$20.00
Regular price
Sold out
Unit price
per 

UChicago Medicine 25th University of Chicago Comprehensive Cancer Center Developmental Therapeutics Symposium 2022

Format: 13 videos + 1 pdf, size: 3.01 GB

Course Audience: oncologist

Overview:

The goals of this activity are to help participants examine synthesized data from completed studies, discuss the novel investigational agents available in ongoing clinical trials, and describe the rationale for and results of studies that include novel agents targeting oncogenic relevant molecular alterations for the treatment of patients with advanced cancer. This knowledge will enable them to appropriately utilize new treatments available to cancer patients, provide support for current and future oncology clinical trials, and become stronger leaders in the area of oncology research. In sum, this program will convey information on how to better implement precision medicine in oncologic care, leading to better outcomes for patients suffering from cancer.

Target Audience

This activity is designed for physicians and other healthcare professionals currently involved in the diagnosis, screening, and treatment of cancer patients.

Learning Objectives

At the conclusion of this activity, participants will be able to:

  • State the clinical effects of novel experimental agents; including but not limited to immunotherapeutic approaches other than PD1 and CTLA4 checkpoint inhibitors, nuclear hormone receptor modulating agents, and epigenetic targeted drugs;
  • Cite the relevant pharmacologic and biologic effects of novel anti-cancer agents through the use of blood and tissue samples as well as standard and novel imaging approaches including novel PET tracer imaging and circulating tumor DNA assays;
  • Identify how to assess patient suitability for participation in ongoing and upcoming cancer clinical trials and projects;
  • Discuss advances in the use of systemic therapies for cancer; including those targeting specific molecular alterations such as DNA repair mutations, specific chromosomal translocations, and tyrosine kinase mutations.

 

Agenda (PDF Format)

Session 1 Age of Cellular Therapy at University of Chicago (Video MP4 Format)

Session 1 Developmental Therapeutics for Biliary Tract Cancers (Video MP4 Format)

Session 1 Emerging strategies for the treatment of NSCLC (Video MP4 Format)

Session 1 Emerging treatment paradigms in head and neck cancer (Video MP4 Format)

Session 1 Myeloma 2022 – Challenges and Path Forward (Video MP4 Format)

Session 1 T cell adoptive therapy for solid tumors (Video MP4 Format)

Session 1 Targeted Progress in the Treatment of Gynecologic Malignancies (Video MP4 Format)

Session 2 Enhancing access to clinical trials for adolescents and young adults with cancer (Video MP4 Format)

Session 2 Integration of Radiotherapy into Developmental Therapeutics- What we have learned (Video MP4 Format)

Session 2 New Developments in Precision Medicine for CU Malignancies (Video MP4 Format)

Session 2 Personalizing Therapeutic Approaches in Leukemia and Myeloid Malignancies (Video MP4 Format)

Session 2 Recent Advances in Pharmacogenomic Applications to Cancer Care (Video MP4 Format)

Session 2 Update on immunotherapy efforts in lymphoma at U of C (Video MP4 Format)